Progress of research on the mechanism of DPP-4 inhibitors in the treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease
Dipeptidyl peptidase 4(DPP-4)inhibitor is a new type of diabetes therapy drug.The main hypoglycemic mechanism of dipeptidyl peptidase 4 inhibitor is to increase endogenous glucagon-like pep-tide 1 by reducing the reduction of enterocagon,thus promoting insulin secretion and inhibiting glucagon secre-tion,and reducing blood glucose level in the body.Type 2 diabetes mellitus(T2DM)and non-alcoholic fatty liver disease(NAFLD)are common types of diseases in clinical,and the incidence is high.T2DM and NAFLD can influence and promote each other.T2DM combined with NAFLD not only tends to increase the risk of cardiovascular diseases and aggravate endocrine and metabolic disorders,but also tends to promote the progression of NAFLD,leading to liver cirrhosis,liver cancer and other malignant lesions.Many studies have shown that DPP-4 inhibitors can effectively reduce blood glucose levels and improve insulin resistance in pa-tients with T2DM and have a good preventive effect on NAFLD.This article reviews the efficacy and safety of DPP-4 inhibitors in the treatment of T2DM with NAFLD.
NETL
NSTL
万方数据
维普
